EcoDrugPlus

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCCRG00000017614
Gene Symbol: ARAF
1 Cross references
188 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCCRG00000017701
Gene Symbol: ARAF
1 Cross references
188 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCCRG00000050317
Gene Symbol: ADAM17
1 Cross references
207 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCCRG00000050647
Gene Symbol: ADAM17
1 Cross references
205 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSCCRG00000060377
Gene Symbol: ADAM17A
1 Cross references
205 Possible Orthologues:

Adam Metallopeptidase Domain 17a

Ensembl ID : ENSCCRG00000002200
Gene Symbol: ADAM17A
1 Cross references
206 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCCRG00000000969
Gene Symbol: ADAMTS5
1 Cross references
195 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCCRG00000031430
Gene Symbol: ADAMTS5
1 Cross references
197 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCCRG00000056926
Gene Symbol: ADRM1
1 Cross references
197 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCCRG00000009064
Gene Symbol: ADRM1
1 Cross references
197 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCCRG00000043683
Gene Symbol: ALK
1 Cross references
192 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSCCRG00000082444
Gene Symbol: APEX1
1 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).